Two heart survivors reunite with life-saving doctors June 20 at Ochsner Lafayette General to celebrate advanced care and ...

The following is a summary of “Endocrine response in cardiogenic shock complicating myocardial infarction: the prognostic value of growth hormone and IGF-1,” published in the May 2025 issue of Journal ...

4 "The DanGer Shock RCT results provide the highest level of scientific evidence demonstrating that Impella CP increases survival in patients with cardiogenic shock secondary to STEMI, which led ...

An international trial of the Impella heart pump in patients with ST elevation myocardial infarction (STEMI) and cardiogenic shock has been stopped by the sponsor Abiomed, Inc. The termination ...

ATLANTA -- Routine use of the Impella CP microaxial flow pump significantly improved survival in patients with infarct-related cardiogenic shock, the randomized DanGer Shock trial showed.

Prior to DanGer-Shock, the effects of temporary mechanical circulatory support with Impella CP in patients with STEMI complicated by cardiogenic shock was unclear, according to the researchers.

Implantation of the Impella CP micro-axial flow pump in the hours after a heart attack significantly increased the rate of survival at six months among people suffering cardiogenic shock ...

confirms routine use of Impella CP in patients who have had a heart attack with STEMI cardiogenic shock reduces 180-day mortality by 12.7%, compared to the control arm (45.8% vs. 58.5% ...

Investigators randomly assigned patients with STEMI and cardiogenic shock to receive the Impella CP plus standard care or standard care alone. The primary endpoint was death from any cause at 180 ...

The main objective of the trial was to assess the efficacy of the microaxial flow pump (Impella CP, Abiomed) in the treatment of patients with STEMI and cardiogenic shock and planned emergency ...